{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:18Z","timestamp":1792699218223,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-024-05437-2","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T02:02:58Z","timestamp":1705629778000},"page":"1765-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"183","author":[{"given":"Lihe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"5437_CR1","doi-asserted-by":"crossref","unstructured":"Lin MT, Wu MH (2017) The global epidemiology of Kawasaki disease: review and future perspectives. Glob Cardiol Sci Pract 3:e201720","DOI":"10.21542\/gcsp.2017.20"},{"issue":"11","key":"5437_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/archdischild-2014-307536","volume":"100","author":"S Singh","year":"2015","unstructured":"Singh S, Vignesh P, Burgner D (2015) The epidemiology of Kawasaki disease: a global update. Arch Dis Child 100(11):1084\u20131088","journal-title":"Arch Dis Child"},{"issue":"6","key":"5437_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/HCO.0b013e3283588f06","volume":"27","author":"LB Daniels","year":"2012","unstructured":"Daniels LB, Gordon JB, Burns JC (2012) Kawasaki disease: late cardiovascular sequelae. Curr Opin Cardiol 27(6):572\u2013577","journal-title":"Curr Opin Cardiol"},{"issue":"17","key":"5437_CR4","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M et al (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135(17):e927\u2013e999","journal-title":"Circulation"},{"issue":"23","key":"5437_CR5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324(23):1633\u20131639","journal-title":"N Engl J Med"},{"issue":"5","key":"5437_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.pcl.2020.06.002","volume":"67","author":"KG Friedman","year":"2020","unstructured":"Friedman KG, Jone PN (2020) Update on the management of Kawasaki disease. Pediatr Clin North Am 67(5):811\u2013819","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"5437_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2008-0730","volume":"124","author":"MB Son","year":"2009","unstructured":"Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR et al (2009) Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 124(1):1\u20138","journal-title":"Pediatrics"},{"issue":"2","key":"5437_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00246-014-1016-1","volume":"36","author":"BS Moffett","year":"2015","unstructured":"Moffett BS, Syblik D, Denfield S, Altman C, Tejtel-Sexson K (2015) Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database. Pediatr Cardiol 36(2):374\u2013378","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"5437_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/jgh.13498","volume":"32","author":"K Hosoi","year":"2017","unstructured":"Hosoi K, Ohtsuka Y, Fujii T, Kudo T, Matsunaga N, Tomomasa T et al (2017) Treatment with infliximab for pediatric Crohn\u2019s disease: nationwide survey of Japan. J Gastroenterol Hepatol 32(1):114\u2013119","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"5437_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1517\/14712598.5.8.1095","volume":"5","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Sieper J (2005) Infliximab for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 5(8):1095\u20131109","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"5437_CR11","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56(9):3096\u20133106","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5437_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0090-1229(88)90088-8","volume":"48","author":"S Furukawa","year":"1988","unstructured":"Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K et al (1988) Peripheral blood monocyte\/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48(2):247\u2013251","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"5437_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0090-1229(90)90166-N","volume":"56","author":"T Matsubara","year":"1990","unstructured":"Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56(1):29\u201336","journal-title":"Clin Immunol Immunopathol"},{"issue":"5","key":"5437_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","volume":"146","author":"JC Burns","year":"2005","unstructured":"Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD et al (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146(5):662\u2013667","journal-title":"J Pediatr"},{"issue":"4","key":"5437_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/03009740600588228","volume":"35","author":"EV Stenbog","year":"2006","unstructured":"Stenbog EV, Windelborg B, Horlyck A, Herlin T (2006) The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol 35(4):318\u2013321","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"5437_CR16","first-page":"808","volume":"31","author":"JE Weiss","year":"2004","unstructured":"Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31(4):808\u2013810","journal-title":"J Rheumatol"},{"issue":"4","key":"5437_CR17","first-page":"453","volume":"24","author":"F Zulian","year":"2006","unstructured":"Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O (2006) Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol 24(4):453","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"5437_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153(6):833\u2013838","journal-title":"J Pediatr"},{"key":"5437_CR19","doi-asserted-by":"crossref","unstructured":"Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S et al (2018) Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 8(1):1994","DOI":"10.1038\/s41598-017-18387-7"},{"key":"5437_CR20","doi-asserted-by":"crossref","unstructured":"Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE et al (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 158(4):644\u2013649.e1","DOI":"10.1016\/j.jpeds.2010.10.012"},{"issue":"4","key":"5437_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/INF.0000000000001039","volume":"35","author":"Y Youn","year":"2016","unstructured":"Youn Y, Kim J, Hong YM, Sohn S (2016) Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatr Infect Dis J 35(4):457\u2013459","journal-title":"Pediatr Infect Dis J"},{"key":"5437_CR22","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.12659\/MSM.908678","volume":"24","author":"CL Han","year":"2018","unstructured":"Han CL, Zhao SL (2018) Intravenous immunoglobulin gamma (IVIG) versus IVIG plus infliximab in young children with Kawasaki disease. Med Sci Monit 24:7264\u20137270","journal-title":"Med Sci Monit"},{"issue":"9930","key":"5437_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","volume":"383","author":"AH Tremoulet","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X et al (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383(9930):1731\u20131738","journal-title":"Lancet"},{"key":"5437_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"5437_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"12","key":"5437_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","volume":"5","author":"JC Burns","year":"2021","unstructured":"Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N et al (2021) Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health 5(12):852\u2013861","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"5437_CR27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3341","volume":"143","author":"A Dionne","year":"2019","unstructured":"Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD et al (2019) Treatment intensification in patients with Kawasaki disease and coronary aneurysm at diagnosis. Pediatrics 143(6):e20183341","journal-title":"Pediatrics"},{"issue":"10","key":"5437_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/INF.0000000000001951","volume":"37","author":"PN Jone","year":"2018","unstructured":"Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glode MP, Dominguez SR (2018) Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J 37(10):976\u2013980","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"5437_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/archdischild-2023-325639","volume":"108","author":"K Miyata","year":"2023","unstructured":"Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC et al (2023) Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Arch Dis Child 108(10):833\u2013838","journal-title":"Arch Dis Child"},{"issue":"5","key":"5437_CR30","first-page":"60","volume":"10","author":"PY Zhang","year":"2018","unstructured":"Zhang PY, Tang CZ, Chi HT, Zhang WT, Qu SQ (2018) Comparison of the effect of infliximab and intravenous immunoglobulin in the treatment of children with Kawasaki disease refractory to initial IVIG therapy. Chin J Front Med Sci 10(5):60\u201363","journal-title":"Chin J Front Med Sci"},{"issue":"7","key":"5437_CR31","first-page":"459","volume":"24","author":"YH Guo","year":"2020","unstructured":"Guo YH, Yu HG, Zhang YY, Huang N, Ma L (2020) Comparison of different treatment regimens in resistant Kawasaki disease. Chin J Rheumatol 24(7):459\u2013462","journal-title":"Chin J Rheumatol"},{"issue":"1","key":"5437_CR32","first-page":"35","volume":"17","author":"Y Peng","year":"2022","unstructured":"Peng Y, Liu XH, Ouyang Q, Duan Z (2022) Treatment of refractory Kawasaki disease with IVIG, infliximab or corticosteroids: a cohort study. Chin J Evid Based Pediatr 17(1):35\u201338","journal-title":"Chin J Evid Based Pediatr"},{"key":"5437_CR33","unstructured":"Qu N, Chen Y, Dong X, Wang QN (2022) Clinical efficacy of infliximab in the treatment of immuneglobulin unresponsive Kawasaki disease. J Guangxi Med Univ 39(3):469\u2013474"},{"issue":"6","key":"5437_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11882-023-01083-0","volume":"23","author":"L Cannon","year":"2023","unstructured":"Cannon L, Campbell MJ, Wu EY (2023) Multisystemic inflammatory syndrome in children and Kawasaki disease: parallels in pathogenesis and treatment. Curr Allergy Asthma Rep 23(6):341\u2013350","journal-title":"Curr Allergy Asthma Rep"},{"issue":"8","key":"5437_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/1756-185X.14816","volume":"26","author":"S Philip","year":"2023","unstructured":"Philip S, Jindal A, Krishna Kumar R (2023) An update on understanding the pathophysiology in Kawasaki disease: possible role of immune complexes in coronary artery lesion revisited. Int J Rheum Dis 26(8):1453\u20131463","journal-title":"Int J Rheum Dis"},{"key":"5437_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12891-015-0744-6","volume":"16","author":"Y Ding","year":"2015","unstructured":"Ding Y, Li G, Xiong LJ, Yin W, Liu J, Liu F et al (2015) Profiles of responses of immunological factors to different subtypes of Kawasaki disease. BMC Musculoskelet Disord 16:315","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"5437_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12865-021-00407-x","volume":"22","author":"Q Wu","year":"2021","unstructured":"Wu Q, Weng R, Xu Y, Wang L, Huang Y, Yang J (2021) Activin a suppresses peripheral CD8(+) T lymphocyte activity in acute-phase Kawasaki disease. BMC Immunol 22(1):17","journal-title":"BMC Immunol"},{"issue":"2","key":"5437_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","volume":"20","author":"N Parameswaran","year":"2010","unstructured":"Parameswaran N, Patial S (2010) Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 20(2):87\u2013103","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"5437_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fped.2019.00018","volume":"7","author":"S Nagata","year":"2019","unstructured":"Nagata S (2019) Causes of Kawasaki disease-from past to present. Front Pediatr 7:18","journal-title":"Front Pediatr"},{"issue":"115\u2013120","key":"5437_CR40","volume":"195","author":"H Masuda","year":"2018","unstructured":"Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T et al (2018) Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan. J Pediatr 195(115\u2013120):e3","journal-title":"J Pediatr"},{"key":"5437_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103946","volume":"78","author":"WT Lei","year":"2022","unstructured":"Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ et al (2022) Pharmacologic interventions for Kawasaki disease in children: a network meta-analysis of 56 randomized controlled trials. EBioMedicine 78:103946","journal-title":"EBioMedicine"},{"issue":"18","key":"5437_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2352-4642(18)30293-1","volume":"2","author":"K Miyata","year":"2018","unstructured":"Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M et al (2018) Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Lancet Child Adolesc Health 2(18):855\u2013862","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"5437_CR43","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1542\/peds.2011-0148","volume":"129","author":"S Ogata","year":"2011","unstructured":"Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M (2011) Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Padiatrics 129(1):e17\u2013e23","journal-title":"Padiatrics"},{"key":"5437_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fped.2020.00195","volume":"8","author":"A Gambacorta","year":"2020","unstructured":"Gambacorta A, Buonsenso D, De Rosa G, Lazzareschi I, Gatto A, Brancato F et al (2020) Resolution of giant coronary aneurisms in a child with refractory Kawasaki disease treated with anakinra. Front Pediatr 8:195","journal-title":"Front Pediatr"},{"issue":"8","key":"5437_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.autrev.2018.01.024","volume":"17","author":"I Kone-Paut","year":"2018","unstructured":"Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP et al (2018) The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev 17(8):768\u2013774","journal-title":"Autoimmun Rev"},{"issue":"5","key":"5437_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1017\/S1047951117002864","volume":"28","author":"MP Guillaume","year":"2018","unstructured":"Guillaume MP, Reumaux H, Dubos F (2018) Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. Cardiol Young 28(5):739\u2013742","journal-title":"Cardiol Young"},{"issue":"8","key":"5437_CR47","volume":"14","author":"K Rajasekaran","year":"2022","unstructured":"Rajasekaran K, Duraiyarasan S, Adefuye M, Manjunatha N, Ganduri V (2022) Kawasaki disease and coronary artery involvement: a narrative review. Cureus 14(8):e28258","journal-title":"Cureus"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05437-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T09:12:30Z","timestamp":1712567550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05437-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5437"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05437-2","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable for meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable for meta-analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}